Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out

被引：2
|
作者：
Schmitt, Andreas Michael [1 ]
Larkin, James [2 ]
Patel, Sapna P. [3 ]
机构：
[1] Univ Hosp Basel, Dept Med Oncol, Basel, Switzerland
[2] Royal Marsden Hosp NHS Fdn Trust, Dept Med Oncol, London, England
[3] Univ Colorado, Dept Med, Div Med Oncol, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 02期
关键词：
ANTIBODY;
D O I：
10.1200/JCO-24-01572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Impact of radio(chemo)therapy on expression of immune checkpoint ligands PD-L1 and PD-L2 on murine and human melanoma cells
    Riegel, D.
    Baeumler, M.
    Spiljar, M.
    Rueckert, M.
    Frey, B.
    Fietkau, R.
    Derer, A.
    Gaipl, U. S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2017, 193 : S132 - S132
  • [22] BRAF inhibition increases exosomal PD-L1 protein expression in melanoma
    Kasumova, Gyulnara G.
    Shi, Alvin
    Cintolo-Gonzalez, Jessica A.
    Chein, Isabel
    Frederick, Dennie T.
    Alpatov, Roman
    Michaud, William A.
    Plana, Deborah
    Panka, David J.
    Corcoran, Ryan B.
    Flaherty, Keith T.
    Sullivan, Ryan J.
    Kellis, Manolis
    Boland, Genevieve M.
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
  • [23] Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma
    Kuempers, Christiane
    Jokic, Mladen
    Haase, Ozan
    Offermann, Anne
    Vogel, Wenzel
    Graetz, Victoria
    Langan, Ewan A.
    Perner, Sven
    Terheyden, Patrick
    FRONTIERS IN MEDICINE, 2019, 6
  • [24] Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
    Nimmagadda, Sridhar
    CANCERS, 2020, 12 (11) : 1 - 26
  • [25] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [26] PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?
    Al-Ahmadie, H.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1658 - 1659
  • [27] A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
    Chatterjee, Samit
    Lesniak, Wojciech G.
    Gabrielson, Matthew
    Lisok, Ala
    Wharram, Bryan
    Sysa-Shah, Polina
    Azad, Babak Behnam
    Pomper, Martin G.
    Nimmagadda, Sridhar
    ONCOTARGET, 2016, 7 (09) : 10215 - 10227
  • [28] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [29] Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
    Melosky, B.
    Chu, Q.
    Juergens, R. A.
    Leighl, N.
    Lonescu, D.
    Tsao, M. -S.
    McLeod, D.
    Hirsh, V.
    CANCER TREATMENT REVIEWS, 2018, 65 : 65 - 77
  • [30] PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival
    Micevic, Goran
    Thakral, Durga
    McGeary, Meaghan
    Bosenberg, Marcus W.
    PIGMENT CELL & MELANOMA RESEARCH, 2019, 32 (03) : 435 - 440
12345